Literature DB >> 34919637

A novel EZH2/NXPH4/CDKN2A axis is involved in regulating the proliferation and migration of non-small cell lung cancer cells.

Zeng Yang1, Bo Wei1, Anbang Qiao1, Popo Yang1, Wenhui Chen1, Dezhi Zhen1, Xiaojian Qiu2.   

Abstract

NXPH4 is discovered to be a neuropeptide-like glycoprotein, belonging to the Neurexophilins (Nxphs) family. NXPH4 shares a similar domain structure with NXPH1, which, however, is poorly understood in terms of its function. Bioinformatics analysis and experimental verification in this study confirmed the abnormal high expression of NXPH4 in non-small cell lung cancer (NSCLC) tissues and cells. Knockdown of NXPH4 by siRNA can inhibit the proliferation and migration of cells, resulting in significant cell cycle arrest in S1 phase. Furthermore, in NSCLC cells, NXPH4 was regulated by transcriptional activation of enhancer of zeste homolog 2 (EZH2) in its upstream. While downstream, NXPH4 could interact with CDKN2A and downregulate its protein stability, thus participating in the cell cycle regulation through interacting with cyclinD-CDK4/6-pRB-E2F signaling pathway. To sum up, the present study reveals a regulatory pathway of EZH2/NXPH4/CDKN2A in NSCLC, providing possible reference for understanding the function of NXPH4 in tumors.
© The Author(s) 2021. Published by Oxford University Press on behalf of Japan Society for Bioscience, Biotechnology, and Agrochemistry.

Entities:  

Keywords:  CDKN2A; EZH2; NSCLC; NXPH4; cyclinD

Mesh:

Year:  2022        PMID: 34919637     DOI: 10.1093/bbb/zbab217

Source DB:  PubMed          Journal:  Biosci Biotechnol Biochem        ISSN: 0916-8451            Impact factor:   2.043


  7 in total

1.  Neurexophilin 4 is a prognostic biomarker correlated with immune infiltration in bladder cancer.

Authors:  Xianchao Sun; Shiyong Xin; Liang Jin; Ying Zhang; Lin Ye
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

2.  UBE2S as a novel ubiquitinated regulator of p16 and β-catenin to promote bone metastasis of prostate cancer.

Authors:  Shengmeng Peng; Xu Chen; Chaoyun Huang; Chenwei Yang; Minyi Situ; Qianghua Zhou; Yihong Ling; Hao Huang; Ming Huang; Yangjie Zhang; Liang Cheng; Qiang Zhang; Zhenghui Guo; Yiming Lai; Jian Huang
Journal:  Int J Biol Sci       Date:  2022-05-16       Impact factor: 10.750

3.  NXPH4 Promotes Gemcitabine Resistance in Bladder Cancer by Enhancing Reactive Oxygen Species and Glycolysis Activation through Modulating NDUFA4L2.

Authors:  Decai Wang; Pu Zhang; Zijian Liu; Yifei Xing'; Yajun Xiao
Journal:  Cancers (Basel)       Date:  2022-08-03       Impact factor: 6.575

Review 4.  Current treatments for non-small cell lung cancer.

Authors:  Qianqian Guo; Liwei Liu; Zelong Chen; Yannan Fan; Yang Zhou; Ziqiao Yuan; Wenzhou Zhang
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

5.  Construction and validation of a prognostic model with RNA binding protein-related mRNAs for the HBV-related hepatocellular carcinoma patients.

Authors:  Shaohua Xu; Hui Liu; Renyun Tian; Jiahui Xie; Su Chen; Junyun Luo; Haizhen Zhu; Yirong Wang; Zhaoyong Li
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

6.  Increased Expression of NXPH4 Correlates with Immune Cell Infiltration and Unfavorable Prognosis in Hepatocellular Carcinoma.

Authors:  Qin Tang; Yue-Ming Chen; Mei-Mei Shen; Wen Dai; Hang Liang; Jun-Nan Liu; Jian Gao
Journal:  J Oncol       Date:  2022-10-06       Impact factor: 4.501

7.  NXPH4 Used as a New Prognostic and Immunotherapeutic Marker for Muscle-Invasive Bladder Cancer.

Authors:  Zhiming Gui; Xiaoling Ying; Chunxiao Liu
Journal:  J Oncol       Date:  2022-10-04       Impact factor: 4.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.